Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Other Non-Current Liabilities (2016 - 2025)

Standard Biotools (LAB) has disclosed Other Non-Current Liabilities for 16 consecutive years, with $1.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Liabilities fell 20.53% to $1.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.2 million, a 20.53% decrease, with the full-year FY2024 number at $1.1 million, changed 0.28% from a year prior.
  • Other Non-Current Liabilities was $1.2 million for Q3 2025 at Standard Biotools, down from $1.2 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $3.5 million in Q1 2025 to a low of $276000.0 in Q2 2021.
  • A 5-year average of $1.3 million and a median of $1.2 million in 2022 define the central range for Other Non-Current Liabilities.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 63.19% in 2023, then surged 412.73% in 2024.
  • Standard Biotools' Other Non-Current Liabilities stood at $882000.0 in 2021, then rose by 8.96% to $961000.0 in 2022, then grew by 10.82% to $1.1 million in 2023, then fell by 0.28% to $1.1 million in 2024, then increased by 12.99% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Other Non-Current Liabilities are $1.2 million (Q3 2025), $1.2 million (Q2 2025), and $3.5 million (Q1 2025).